Category Archives: Stem Cell Therapy

ZUTPHEN, the Netherlands, April 24, 2012 /PRNewswire/ --

In line with its continuous efforts to improve internal stem cell procedures, Cryo-Save proudly announces the appointment of the highly knowledgeable stem cell expert Dr. Marcin Jurga. Dr. Jurga will supervise new process validation at the Cryo-Save labs and study new processing techniques for umbilical cord blood, cord tissue and fat tissue, to ensure quality and use of the highest technology available on the market.

Marcin Jurga is specialized in adult stem cells biology, neuroscience and tissue engineering. His field of interest focuses on developing new methods for adult stem cell applications in in-vitro toxicology and regenerative medicine. Part of his validation study and internal research at Cryo-Save includes studies on fresh and frozen cells isolated from fat tissue and cord tissue, to explain the quality of these and their ability for extensive growth in vitro and multilineage differentiation.

"Cryo-Save is truly committed to the advancement of stem cell therapy. Storing stem cells is utterly important and our core business, but we are also committed to increasing the potential use of these stem cells and building the tools needed to tackle un-met medical needs with stem cells", said Arnoud Van Tulder, CEO of Cryo-Save.

Dr. Jurga is an experienced stem cell researcher with broad international experience; he was team leader and senior researcher at the Cell Therapy Research Institute in Lyon, France and previously completed a post doc at the Centre for Life, Newcastle University in the UK. He got Ph.D. degree in Poland, at the Mossakowski Medical Research Centre of Polish Academy of Sciences in Warsaw. In May, Dr. Jurga is also planning to get a habilitation degree at Lyon 1 Claude-Bernard University in France. The habilitation thesis entitled: "Stem Cell Therapy and Neutral Tissue Engineering in Regeneration of Central Nervous System".

Cryo-Save, the leading international family stem cell bank, stores more than 200,000 samples from umbilical cord blood, cord tissue and adipose tissue. There are already many diseases treatable by the use of stem cells, and the number of treatments will only increase. Driven by its international business strategy, Cryo-Save is now represented in over 40 countries on four continents, with ultra-modern processing and storage facilities in the United States, Belgium, Germany, Dubai, India, South Africa and France (validation in progress).

Cryo-Save: http://www.cryo-save.com/group

Cryo-Save Group N.V.

1

Read more:
Cryo-Save Hires Stem Cell Expert in the Flagship Lab in Niel, Belgium

SOUTH SAN FRANCISCO, CA--(Marketwire -04/25/12)- VistaGen Therapeutics, Inc. (VSTA.OB - News) (VSTA.OB - News), a biotechnology company applying stem cell technology for drug rescue, has secured a new United States patent covering the company's proprietary methods used to measure and type the toxic effects produced by drug compounds in liver stem cells.

Test methods included in this new patent, (U.S. Patent 11/445,733), titled "Toxicity Typing Using Liver Stem Cells," cover all mammalian liver stem cells -- rat and mouse cells, for example, in addition to human cells. Liver stem cells used in drug testing can be derived from in vivo tissue or produced from embryonic stem cells (ES) or induced pluripotent stem cells (iPS).

H. Ralph Snodgrass, Ph.D., VistaGen's President and Chief Scientific Officer, said, "This patent covers the monitoring of changes in gene expression as an assay for predicting drug toxicities. It is well known that drugs activate and suppress specific genes, and that the changes in gene expression reflect the mechanism of drug toxicities. The specific sets of genes that are affected become a profile of that drug."

VistaGen's new patent also covers techniques used to develop a database of gene expression profiles of drugs that have the same type of liver toxicity. Using sophisticated "pattern matching" database tools, drug developers can analyze these related profiles to determine "gene expression signatures" that are common and predictive of drugs that produce specific types of toxicity.

"Without this database capability, a drug's single gene expression profile could not be interpreted," Dr. Snodgrass added. "The ability to use liver stem cells to differentiate drug-dependent gene expression profiles, and to compare those profiles of drugs known to induce toxic liver effects, provides a powerful tool for predicting liver toxicity of new drug candidates, including drug rescue variants."

Shawn K. Singh, VistaGen's Chief Executive Officer, stated, "Strong and enforceable intellectual property rights are critical components of our plan to optimize the commercial potential of our Human Clinical Trials in a Test Tube platform. This new liver toxicity typing patent further solidifies our growing IP portfolio, and supports the continuing development of LiverSafe 3D, our human liver cell-based bioassay system, which complements our CardioSafe 3D human heart cell-based bioassay system for heart toxicity."

About VistaGen Therapeutics

VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue and cell therapy. VistaGen's drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube, with modern medicinal chemistry to generate new chemical variants (Drug Rescue Variants) of once-promising small-molecule drug candidates. These are drug candidates discontinued due to heart toxicity after substantial development by pharmaceutical companies, the U.S. National Institutes of Health (NIH) or university laboratories. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans, bringing human biology to the front end of the drug development process.

Additionally, VistaGen's small molecule drug candidate, AV-101, is in Phase 1b development for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects approximately 1.8 million people in the U.S. alone. VistaGen is also exploring opportunities to leverage its current Phase 1 clinical program to enable additional Phase 2 clinical studies of AV-101 for epilepsy, Parkinson's disease and depression. To date, VistaGen has been awarded over $8.5 million from the NIH for development of AV-101.

Visit VistaGen at http://www.VistaGen.com, follow VistaGen at http://www.twitter.com/VistaGen or view VistaGen's Facebook page at http://www.facebook.com/VistaGen

More here:
VistaGen Secures Key U.S. Patent Covering Stem Cell Technology Methods Used to Test Drug Candidates for Liver Toxicity

Oakland Raiders linebacker Rolando McClain turned to stem-cell therapy to deal with the aches and pains that come with being a professional football player, the Mobile Press-Register reported Sunday.

Reuter: Impact LB prospects

According to the newspaper, McClain, who missed only one game last season but was hampered by knee pain and an ankle injury, had stem cells taken from his own fat and injected into his knee and leg. McClain credits the procedure for helping him do what he needs to do to prepare for the 2012 season.

"It feels a lot better," McClain told the newspaper, adding he has been able to work out "with hardly any pain at all."

Jason R. Williams, the radiologist who performed the procedure in Alabama, called the experimental therapy "the future of medicine." However, the newspaper also reported that the FDA has warned consumers about the possible pitfalls of stem-cell treatments.

"There is a potential safety risk when you put cells in an area where they are not performing the same biological function as they were when in their original location in the body," said Stephanie Simek, deputy director of the FDA's Office of Cellular, Tissue and Gene Therapies, in a statement.

The newspaper reported that McClain and fellow University of Alabama product Marquis Maze have sought the treatment. Peyton Manning, who recently joined the Denver Broncos after missing the 2011 season with neck issues, reportedly also had a similar procedure outside of the country.

While McClain might be feeling healthier, he has other issues to contend with this offseason. The Birmingham News reported earlier this month that the two-year NFL veteran settled with an Alabama student who claimed McClain struck him with a vehicle and physically assaulted him.

According to the News, McClain also is facing a May 17 trial after allegedly firing a gun in an altercation with a man in November.

More:
Raiders' Rolando McClain: Stem-cell therapy worked well

GRAND RAPIDS, Mich., April 19, 2012 /PRNewswire/ --Researchers at Lund University in Sweden have discovered a new stem cell in the adult brain. These cells can proliferate and form several different cell types -- most importantly, they can form new brain cells. Scientists hope to take advantage of the finding to develop methods to heal and repair disease and injury in the brain.

Analyzing brain tissue from biopsies, the researchers for the first time found stem cells located around small blood vessels in the brain. The cell's specific function is still unclear, but its plastic properties suggest great potential.

"A similar cell type has been identified in several other organs where it can promote regeneration of muscle, bone, cartilage and adipose tissue," said Patrik Brundin, M.D., Ph.D., Jay Van Andel Endowed Chair in Parkinson's Research at Van Andel Research Institute (VARI), Head of the Neuronal Survival Unit at Lund University and senior author of the study.

In other organs, researchers have shown clear evidence that these types of cells contribute to repair and wound healing. Scientists suggest that the curative properties may also apply to the brain. The next step is to try to control and enhance stem cell self-healing properties with the aim of carrying out targeted therapies to a specific area of the brain.

"Our findings show that the cell capacity is much larger than we originally thought, and that these cells are very versatile," said Gesine Paul-Visse, Ph.D., Associate Professor of Neuroscience at Lund University and the study's primary author. "Most interesting is their ability to form neuronal cells, but they can also be developed for other cell types. The results contribute to better understanding of how brain cell plasticity works and opens up new opportunities to exploit these very features."

The study, published in the journal PLoS ONE, is of interest to a broad spectrum of brain research. Future possible therapeutic targets range from neurodegenerative diseases to stroke.

"We hope that our findings may lead to a new and better understanding of the brain's own repair mechanisms," said Dr. Paul-Visse. "Ultimately the goal is to strengthen these mechanisms and develop new treatments that can repair the diseased brain."

Link to the study here:

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0035577

About the Neuronal Survival Unit, Faculty of Medicine, Lund University

Read this article:
New Stem Cell Found in the Brain

17-04-2012 12:49 Former major league baseball player undergoes a controversial stem cell therapy for a second chance at the Major Leagues.

Excerpt from:
CJ Nitkowski: The Last Season - Part 1 - Video

Lifesaving stem cell treatments must be offered in Ireland, says expert

By Sen McCrthaigh

Thursday, April 19, 2012

Ireland is seriously lagging behind most other countries in offering live-saving treatments provided by the use of adult stem cells, a leading international medical expert has warned.

Colin McGuckin called on the Government and health authorities to facilitate the wider collection and storage of stem cells from umbilical cord blood in Ireland.

Prof McGuckin who is advisor to the Vatican on stem cells and a director of the Cell Therapy Research Institute in Lyon, France is director of the Adult Stem Cell Foundation of Ireland, which was formally launched yesterday.

"Treatments which are available in other countries must come to Ireland," said Mr McGuckin. He also expressed fears the lack of stem cell therapies here could force people to seek unregulated care abroad.

Presently, none of Irelands three main maternity hospitals allow for the collection of adult stem cells from umbilical cords except in high-risk cases.

The only facility which allows the practice is Mount Carmel Hospital in Dublin. All adult stem cells collected are sent abroad for storage.

Mr McGuckin said adult stem cells could be used in the treatment of over 70 diseases including leukaemia and heart disease. Advances are also being made in their use for neurological diseases such as Alzheimers.

The rest is here:
Lifesaving stem cell treatments must be offered in Ireland, says expert

From Rogaine to hair plugs, there have been many strides made to induce hair regrowth for bald or balding heads, but a new Japanese study found a possible cure to baldness by using stem cells.

Using stem cell therapy, scientists at the Tokyo University of Science in Japan led by Takashi Tsuki gave a hairless mouse a Mohawk by regenerating hair follicles.

Researchers used follicles from a normal mouse, namely adult epithelial stem cells and dermal papilla cell found in the skin, to create a "seed" of a hair follicle. Then, they implanted the newly-created "seed" using intracutaneous transplantation into the hairless mouse and -- Voila! -- hair.

According to the research published in Nature Communications, functional hair follicles grew on the hairless mouse properly on the skin in the epidermis, arrector pili muscle and nerve fibers. The newly regrown hair also went through a standard hair cycle of shedding and regrowth.

"Our current study thus demonstrates the potential for not only hair regeneration therapy but also the realisation of bioengineered organ replacement using adult somatic stem cells," the report said.

The baldness cure that worked on the hairless mice, however, has not yet been tested on humans, but the researchers hope to introduce the idea soon.

"We would like to start clinical research within three to five years, so that an actual treatment to general patients can start within a decade," researcher Koh-ei Toyoshima said in a statement.

However, even if it does work on people, the issue is raised about the cost, as stem cell therapy practices can be quite costly.

View the video of the hairless mouse with hair regrowth below.

See the original post:
Baldness Cure: Japanese Study Finds Stem Cells Induce Hair Regrowth for Bald Heads on Mouse [PHOTO & VIDEO]

Photo by Allie Garza

Dr. Zannos Grekos, a cardiologist whose practice is in Bonita Springs, speaks with a seminar attendant after one of his educational seminars about stem cell treatment, using one's own stem cells, for treating heart disease and other medical conditions, on Monday, March 14, 2011, at the Collier County Library. Allie Garza/Staff

K.K.Yankopolus

In a case involving a criminal investigation into the recent death of a 77-year-old man after stem cell treatment, state health authorities say Dr. Zannos Grekos extracted tissue from the patient while a second doctor later injected the patient with his own concentrated stem cells.

But when Grekos, a Bonita Springs cardiologist, initially harvested fatty tissue from Richard Poling's stomach on March 2, he unknowingly damaged the patient's abdomen which led to bleeding, according to a state Department of Health complaint.

New documents obtained by the Daily News shed more light on the case of Grekos and Dr. Konstantine Yankopolus, a Fort Myers obstetrician who assisted Grekos. They face potential disciplinary action from the state Board of Medicine for doing a stem cell treatment that the state says was experimental and dangerous.

The state issued separate administrative complaints against them in late March and early April, a few weeks after Poling died the same day of the treatment. He suffered a cardiac arrest in Grekos' practice on Bonita Beach Road and was pronounced dead at NCH North Naples Hospital.

The Lee County Sheriff's Office launched a criminal investigation in early March and it is ongoing, agency spokesman Larry King said.

Grekos also faces potential discipline when the state restricted his license in February, 2011 in connection to the death of a 69-year-old woman who went to him in 2010 for stem cell therapy.

She sought a remedy for neurological damage after chemotherapy for breast cancer. She fell in her home after the treatment, suffered a brain injury and later was taken off life support.

See the original post here:
State: Grekos extracted tissue from stem cell patient who died, damaged patient's abdomen